{
  "docId": "019de070-2277-75da-968a-7dffc3addc7d",
  "docSlug": "9a22f83671fc7371cae4ff7d98099963",
  "documentTitle": "Fusion Pharmaceuticals | IPO Presentation Deck | 49 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 49,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "appendix_data",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-2277-75da-968a-7dffc3addc7d/21",
  "deckHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d",
  "deckJsonHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d.json",
  "deckAnchorHref": "/decks/019de070-2277-75da-968a-7dffc3addc7d#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.15
      },
      "kind": "list",
      "text": "Findings: Reversible myelosuppression, no evidence of toxicity to kidney/bladder/intestines/lung, FDA approved IND without Spironolactone",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32e43ae6-0b22-4b38-b2eb-55ac3ca337a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "Overview: FPI-1175 studies, Dosimetry study with FPI-1434, Dose range-finding study, GLP late radiation toxicity study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8b0ec1c-11ea-4271-90eb-d9454683a7f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 1,
        "x": 0,
        "y": 0.93
      },
      "kind": "title",
      "text": "Preclinical data supported moving in to Phase 1 trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d936983-4e89-44a6-ad48-e7ef0e18dcd6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Toxicology Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ce6a837-6b12-4358-91b3-a16081073db7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 19,
      "beatId": "808eda63-f5f8-4631-9599-1a2134d2ac37",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents data and results from Fusion Pharmaceuticals' clinical trials, demonstrating its progress and potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}